Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.9940
Oct 09 • 3:59 PM ET Dollar change-0.0360 Percentage change(-3.50%)
Aftermarket Close
0.9801
Aftermarket • 7:53 PM ET Dollar change-0.0139 Percentage change(-1.40%)
Index
RUT
Market Cap
251.39M
Enterprise Value
201.74M
Income
-32.26M
Sales
13.08M
Book/sh
0.24
Cash/sh
0.20
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
77
IPO
Mar 05, 1992
P/E
-
Forward P/E
-
PEG
-
P/S
19.22
P/B
4.13
P/C
4.95
P/FCF
-
EV/EBITDA
-
EV/Sales
15.42
Quick Ratio
6.61
Current Ratio
6.61
Debt/Eq
0.04
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
-0.18
EPS next Y
-0.10
EPS next Q
-0.03
EPS this Y
79.08%
EPS next Y
-65.86%
EPS next 5Y
-
EPS past 3/5Y
-21.30% -14.94%
Sales past 3/5Y
-0.33% 79.88%
EPS Y/Y TTM
23.17%
Sales Y/Y TTM
19.87%
EPS Q/Q
77.21%
Sales Q/Q
-61.34%
Insider Own
24.81%
Insider Trans
0.00%
Inst Own
26.67%
Inst Trans
2.58%
ROA
-32.75%
ROE
-59.03%
ROIC
-51.81%
Gross Margin
93.81%
Oper. Margin
-205.23%
Profit Margin
-246.58%
SMA20
0.45%
SMA50
-5.44%
SMA200
-27.94%
Trades
Shs Outstand
252.91M
Shs Float
190.16M
52W High
2.09 -52.44%
52W Low
0.88 12.66%
Volatility
6.27% 6.72%
ATR (14)
0.06
RSI (14)
48.83
Beta
1.70
Rel Volume
1.00
Avg Volume
1.16M
Volume
1,158,581
Perf Week
6.85%
Perf Month
-2.55%
Perf Quarter
-17.85%
Perf Half Y
-32.84%
Perf YTD
-40.48%
Perf Year
-43.20%
Perf 3Y
-22.95%
Perf 5Y
-58.58%
Perf 10Y
-65.02%
Prev Close
1.03
Price
0.99
Change %
-3.50%
Date Action Analyst Rating Change Price Target Change
Apr-28-26Initiated Canaccord Genuity Buy $9
Aug-20-24Initiated Craig Hallum Buy $4
Nov-02-22Initiated Robert W. Baird Outperform $5
Jun-14-22Initiated B. Riley Securities Buy $4
Aug-19-21Initiated Noble Capital Markets Outperform $8
Mar-31-21Initiated Cantor Fitzgerald Overweight $6
Sep-08-26 08:00AM
Aug-07-26 08:30AM
01:12AM
Aug-06-26 04:42PM
04:01PM
08:00AM Loading…
Jul-30-26 08:00AM
Jul-13-26 08:00AM
Jul-06-26 08:00AM
May-20-26 09:50AM
May-13-26 08:30AM
01:02AM
May-12-26 04:07PM
04:01PM
May-05-26 08:00AM
May-04-26 08:00AM
08:00AM Loading…
Apr-13-26 08:00AM
Apr-10-26 09:55AM
Mar-24-26 08:00AM
Mar-18-26 10:00AM
Mar-06-26 08:30AM
05:47AM
Mar-05-26 05:30PM
04:01PM
Mar-03-26 09:15AM
Feb-26-26 05:30PM
08:00AM
Jan-29-26 01:31PM
Dec-16-25 11:53AM
Nov-07-25 12:01AM
Nov-06-25 05:20PM
04:13PM Loading…
04:13PM
Oct-10-25 09:57AM
Sep-29-25 12:56AM
Sep-23-25 07:23PM
Aug-13-25 03:12AM
Aug-12-25 05:10PM
04:09PM
04:01PM
Aug-07-25 08:45AM
Aug-06-25 06:05PM
Aug-05-25 08:00AM
Aug-04-25 08:00AM
Jul-02-25 05:41AM
Jun-23-25 07:00AM
Jun-05-25 08:00AM
May-14-25 11:39AM
08:00AM
03:14AM
May-13-25 05:10PM
04:01PM
May-12-25 05:45PM
08:00AM
May-01-25 08:00AM
Apr-22-25 08:00AM
Apr-21-25 08:00AM
Mar-11-25 11:12AM
03:02AM
Mar-10-25 05:25PM
04:05PM
Mar-05-25 08:00AM
Feb-12-25 05:37AM
Feb-11-25 08:00AM
Feb-04-25 08:00AM
Jan-30-25 12:00PM
Jan-27-25 04:05PM
Jan-06-25 08:00AM
Jan-04-25 08:10AM
Dec-17-24 09:35AM
Dec-03-24 02:55AM
Nov-21-24 05:00PM
09:35AM
Nov-20-24 08:00AM
Nov-15-24 04:00PM
Nov-14-24 05:15PM
04:01PM
Nov-07-24 08:00AM
Oct-14-24 08:00AM
Oct-09-24 05:52PM
12:00PM
Sep-25-24 08:00AM
Sep-18-24 08:00AM
Aug-13-24 08:00AM
Aug-08-24 06:35PM
04:05PM
Aug-01-24 08:00AM
Jul-02-24 08:00AM
May-30-24 08:00AM
May-21-24 08:00AM
May-10-24 04:40PM
03:49PM
02:09PM
May-09-24 04:01PM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-30-24 08:00AM
Apr-29-24 04:30PM
Apr-19-24 12:13PM
Apr-01-24 08:00AM
Mar-18-24 10:31AM
08:00AM
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
M.B.A.Mr. Brian M. Culley M.A.
Chief Financial OfficerMs. Jill Ann Howe
J.D.Mr. George A. Samuel III
Director of Investor RelationsMs. Ioana C. Hone
Vice President of Corporate Strategy & DevelopmentDr. Charlotte Hubbert Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Culley Brian MPresident and CEOMar 12 '26Buy1.6215,00024,375255,516Mar 12 04:05 PM